Perioperative management of anticoagulation in the patient with the antiphospholipid syndrome in cardiac surgery and cardiac interventions

Perioperative Management of Patients with Rheumatic Disease

Volumn , Issue , 2013, Pages 109-127

  Bartholomew, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Cardiac surgery; Thrombosis

Indexed keywords

EID: 84901318832     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-2203-7_9     Document Type: Chapter

References (112)

1. Galli M. The antiphospholipid triangle. J Thromb Haemost. 2009;8:234-6.
2. Park KW. The antiphospholipid syndrome. Int Anesthesiol Clin. 2004;42:45-57.
3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classi fication criteria for de finite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
4. Cartwright BL, Bean M, Cooper JO. Lupus anticoagulant, antiphospholipid syndrome and cardiac surgery. Anaesth Intensive Care. 2010;38:364-9.
5. Gurlek A, Pamir G, Ozdol C, et al. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J. 2005;46:631-8.
6. Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574-9.
7. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-63.
8. Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome; analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37:154-8.
9. Cervera R, Khamsata MA, Font J, et al. High prevalence of signi ficant heart valve lesions in patients with the primary antiphospholipid syndrome. Lupus. 1991;1:43-7.
10. Christodoulou C, Sangle S, D'Cruz DP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology. 2007;46:907-10.
11. Grzybczak R, Undas A, Rostoff P, et al. Life-threatening cardiac manifestations of primary antiphospholipid syndrome. Heart Vessels. 2010;25:267-9.
12. Roldan C. A valvular and coronary heart disease in systemic in flammatory diseases. Heart. 2008;94:1089-101.
13. Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr. 2009;22:1100-8.
14. George D, Erkan D. Antiphospholipid syndrome. Prog Cardiovasc Dis. 2009;52:115-25.
15. East CJ, Clements F, Matthew J, Slaughter T. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg. 2000;90:1098-101.
16. Hamsten A, Norberg R, Bjorkholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet. 1986;1(8473):113-5.
17. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome. Arthritis Rheum. 2002;46:1019-27.
18. Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32:491-507.
19. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am. 2008;22:79-94.
20. Shi W, Krillis SA, Chong BH, et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20:231-6.
21. Vila P, Hernandez MC, Lopez-Fernandez MF. Prevalence, follow up and clinical signi ficance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72:209-13.
22. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome. JAMA. 2006;295:1050-7.
23. Jervis K, Senthilnathan V, Lerner AB. Management of a patient with lupus anticoagulant and antiphospholipid syndrome for off-pump coronary artery bypass grafting using the Hepcon® system. Anesth Analg. 2009;108:1116-9.
24. Hegde VAP, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome - a case series. Heart Lung Circ. 2007;16:423-7.
25. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991;66:520-4.
26. Bruce IN, Clark-Soloninka CA, Spitzer KA, et al. Prevalence of antibodies in beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833-7.
27. Gorki H, Malinovski V, Stanbridge RDL. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168-81.
28. Hojnik M, George J, Ziporen L, et al. Heart valve involvement (Libman-Sacks endocarditis in the antiphospholipid syndrome). Circulation. 1996;93: 1579-87.
29. Nesher G, Ilany J, Rosenmann D, et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features and treatment. Semin Arthritis Rheum. 1997;27:27-35.
30. Galve E, Ordi J, Barquinero J, et al. Valvular heart disease in primary antiphospholipid syndrome. Ann Intern Med. 1992;16:293-8.
31. Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid syndrome. Am J Cardiol. 2001;87:663-6.
32. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in nonsystemic lupus erythematosus patients: a controlled prospective study. Am J Med. 1996;101:381-6.
33. Vaarala O, Manttari M, Manninen V, et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-7.
34. Farsi A, Domeneghetti MP, Fedi S, et al. High prevalence of anti-ß2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity. 1999;30:93-8.
35. Brey RL, Abbott RD, Curb JD, et al. Beta-2-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32:1701-6.
36. Bick RL, Arun B, Frenkel EP. Antiphospholipid thrombosis syndromes. Haemostasis. 1999;29:100-10.
37. Erdogan D, Goren MT, Diz-Kuckkaya R, et al. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592-6.
38. Turiel M, Muzzupappa S, Gottardi B. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406-12.
39. Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127:414-20.
40. Ciocca RG, Choi J, Graham AM. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg. 1995;170:198-200.
41. Massoudy P, Cetin SM, Thielmann M, et al. Antiphospholipid syndrome in cardiac surgery - an underestimated coagulation disorder. Eur J Cardiothorac Surg. 2005;28:133-7.
42. Weiss S, Nyzio JB, Cines D, Detre J, Milas BL, Narula N, Floyd TF. Antiphospholipid syndrome: intraoperative and postoperative anticoagulation in cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:735-9.
43. Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass graft failure - an autoimmune phenomenon? Lancet. 1986;2:1353-7.
44. Ludia C, Domenico P, Monia C, et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty. Autoimmunity. 1998;27:141-8.
45. Chambers JD, Haire WD, Deligonul U. Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Am Heart J. 1996;132:189-90.
46. Su HM, Lee KT, Chu CH, et al. Acute thrombosis after elective direct intracoronary stenting in primary antiphospholipid syndrome: a case report. Kaohsiung J Med Sci. 2003;19:177-82.
47. Weissman A, Coplan NL. Antiphospholipid antibody syndrome and acute stent thrombosis. Rev Cardiovasc Med. 2006;7:244-6.
48. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73-92.
49. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
50. Boehringer Ingelheim. Pradaxa (dabigatran etexilate package insert). Ridge field. 2010.
51. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation. 2005;112:1286-92.
52. Mangano DT. Multicenter study of perioperative ischemia research: aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309-17.
53. Topol E. Aspirin with bypass surgery: from taboo to new standard of care. N Engl J Med. 2002;347:1359-60.
54. Alexander JH, Berger PB, Ha fley G et al. Impact of early clopidogrel use on angiographic and clinical outcomes following coronary artery bypass surgery; findings from PREVENT IV. J Am Coll Cardiol. 2006;47(suppl A) (4):178A.
55. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006;48:281-6.
56. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
57. Douketis JD, Johnson JA, Turpie AG. Low-molecularweight- heparin as bridging anticoagulation during interruption of warfarin; assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-26.
58. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. The eighth ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2008;133(suppl):299S-339.
59. Landenhed M, Johansson M, Eringe D, et al. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J. 2010;44(2):100-6.
60. Selke FW, DiMaio JM, Caplan LR, et al. Comparing on-pump and off-pump coronary artery bypass grafting: numerous studies but few conclusions: a scienti fic statement from the American Heart Association Council on cardiovascular surgery and anesthesia in collaboration with the interdisciplinary working group on quality of care and outcomes research. Circulation. 2005;111:2858-64.
61. Hirose H, Amano A, Takahashi A. Off-pump coronary artery bypass grafting for elderly patients. Ann Thorac Surg. 2001;72:2013-9.
62. Hoff SJ, Ball SK, Coltharp WH, et al. Coronary artery bypass in patients 80 years and over; is off-pump the operation of choice? Ann Thorac Surg. 2002; 74:S1340-3.
63. Sabik JF, Blackstone EH, Lytle BW, et al. Equivalent midterm outcomes after off-pump and on-pump coronary surgery. J Thorac Cardiovasc Surg. 2004;127:142-8.
64. Horimoto S, Horimoto H, Sawada Y, et al. Off-pump coronary artery bypass in a patient with the antiphosopholipid syndrome. J Cardiovasc Surg. 2005;46:81-3.
65. Maddali MM, Albahrani MJ. Lupus anticoagulant and off-pump coronary bypass; dilemma of anticoagulation. Asian Cardiovasc Thorac Ann. 2007;15:246-8.
66. Casati V, Gerli C, Franco A, et al. Activation of coagulation and fibrinolysis during coronary surgery: on pump versus off-pump techniques. Anesthesiology. 2001;95:1103-9.
67. Tanaka KA, Thourani VH, Williams WH, et al. Heparin anticoagulation in patients undergoing offpump and on-pump coronary bypass surgery. J Anesth. 2007;21:297-303.
68. Gillinov AM, Cosgrove DM. Current status of mitral valve repair. Am Heart Hosp J. 2003;1:47-54.
69. Bonow RO, Carabello BA, Chatterjee K, et al. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation. 2008;118: e523-660.
70. Bouma W, Klinkenberg TJ, van der Horst ICC, et al. Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg. 2010;5:1-13.
71. Yun KI, Miller DC. Mitral valve repair versus replacement. Cardiol Clin. 1991;9:315-27.
72. Horrow JC, Mueksch JN. Coagulation testing. In: Gravlee G, Davis RF, Stammers AH, et al., editors. Cardiopulmonary bypass: principles and practice. Philadelphia: Lippincott; 471. p. 459-71.
73. Myers GJ, Hirsch GM. Double valve replacement in a patient with anticardiolipin syndrome. Perfusion. 1999;14:397-401.
74. Kato Y, Isobe F, Sasaki Y, et al. Secondary mitral valve replacement in antiphospholipid syndrome and chronic renal failure. Jpn J Thorac Cardiovasc Surg. 2001;49:728-31.
75. Fitzgerald DJ, Patel A, Body SC, et al. The relationship between heparin level and activated clotting time in the adult cardiac surgery. Perfusion. 2009;24:93-6.
76. Shuhaibar MN, Hargrove M, Millat MH, et al. How much heparin do we really need to go on pump? A rethink of current practices. Eur J Cardiothorac Surg. 2004;26:947-50.
77. Tanaka K, Takao M, Yada I, et al. Alteration in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth. 1989;3:181-8.
78. Weisinger AS, Levy JH. Current hematologic issues in cardiac surgery and cardiopulmonary bypass. Sem Cardiothorac Vasc Anesth. 1998;2:259-71.
79. Olson Jd, Arkin CF, Brandt JT, et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med. 1998;122:782-98.
80. Sheikh F, Lechiowicz A, Setlur R, Rauch A, Dunn H. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1997;11:764-6.
81. Brownstein L, Bartholomew TP, Silver DG, Berry CM. A case report of mitral valve replacement in a patient with lupus antibody syndrome. Perfusion. 2003;18:373-6.
82. Lango R, Pawlaczyk R, Raszeja-Specht A, Smolenski RT, Rogowski J, Rutkowski B, Szutowicz A. Aortic valve replacement and perioperative management in hemodialyzed patient with antiphospholipid syndrome. Int J Artif Organs. 2004;27:69-73.
83. Ducart AR, Collard EL, Osselaer JC, et al. Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothorac Vasc Anesth. 1997;11:878-9.
84. Lennon MJ, Thackray NM, Gibbs NM. Anti-factor Xa monitoring of anticoagulation during cardiopulmonary bypass in a patient with antiphospholipid syndrome. Anaesth Intensive Care. 2003;31:95-8.
85. Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction. American College of Chest Physicians evidencebased clinical practice guidelines (8th ed). Chest. 2008;133: 708S-75S
86. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation. 2006;113:e166-286.
87. Badak O, Guneri S, Kirimli O, et al. Primary stenting in a patient with acute myocardial infarction and primary antiphospholipid syndrome. J Invasive Cardiol. 2002;14:194-7.
88. Jankowski M, Dudek D, Dubiel JS, et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis. 1998;9:753-6.
89. Musuraca G, Imperadore F, Terraneo C, et al. Successful treatment of post-exertion acute myocardial infarction by primary angioplasty and stenting in a patient with antiphospholipid antibody syndrome. Blood Coagul Fibrinolysis. 2004;15:95-8.
90. Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart. 1998;79:96-8.
91. Timurkaynak T, Cemri M, Ozdemir M, et al. Primary angioplasty and stenting in a patient with primary antiphospholipid syndrome and thrombocytopenia. J Invasive Cardiol. 2001;13:395-400.
92. Umesan CV, Kapoor A, Nityanand S, et al. Recurrent acute coronary events in a patient with primary antiphospholipid syndrome; successful management with intracoronary stenting. Int J Cardiol. 1999;71:99-102.
93. Santrach PJ. Devices for monitoring heparin and protamine in the operating room. Sem Cardiothorac Vasc Anesth. 2003;7:379-85.
94. Despotis GJ, Joist JH, Hogue Jr CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995; 110:46-54.
95. Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood. 1998;91:1999-2004.
96. Erkan D, Leibowitz E, Berman J, et al. Perioperative medical management of antiphospholipid syndrome; hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29: 843-9.
97. Perry DJ, Fitzmaurice DA, Kitchen S, et al. Point of care testing in haemostasis. Br J Haematol. 2010;150:501-14.
98. Green JA, Spiess BD. Current status of anti fibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest. Anesthesiol Clin North Am. 2003;21:527-51.
99. Munoz JJ, Birkmeyer NJO, Birkmeyer JD, et al. Is (epsilon)-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A metaanalysis. Circulation. 1999;99:81-9.
100. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236-61.
101. Royston D. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing post-operative bleeding. Blood Coagul Fibrin. 1990;1:55-69.
102. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. 1998;92:1652-60.
103. Henry D, Carless P, Fergusson D, et al. The safety of aprotinin and lysine-derive anti fibrinolytic drugs in cardiac surgery: a meta analysis. CMAJ. 2009;180:183-93.
104. Aren C. Heparin and protamine during cardiac surgery. Perfusion. 1989;4:171-81.
105. Teoh KKT, Young E, Blackall ME, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;12:211-9.
106. Englberger L, Streich M, Tevaeari H, et al. Different anticoagulation strategies in off-pump coronary artery bypass operations: a European survey. Interact Cardiovasc Thorac Surg. 2008;7:378-82.
107. Andersen MN, Mendelow M, Alfano CA. Experimental studies of heparin-protamine activity with special reference to protamine inhibition of clotting. Surgery. 1959;46:1060-8.
108. Dornan RIP. Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth. 2004;5:748-54.
109. Mariani MA, Gu YJ, Boonstra PW, et al. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg. 1999;67:1370-5.
110. Dunn AS, Spyropoulous A, Turpie AG. Bridging therapy in patients on long term oral anticoagulation who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211-8.
111. Turpie AG, Douketis JD. Enoxaparin is effective and safe in bridging anticoagulation in patients with a mechanical prosthetic heart valve who require temporary interruption of warfarin because of surgery or an invasive procedure. Blood. 2004;104:202A.
112. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-63.